Football Association of Wales (FAW) chief executive Noel Mooney has revealed the "legacy" role of Wrexham owners Ryan ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Stoke Therapeutics (STOK) to $28 from $29 and keeps a Buy rating on the shares. The ...

Stoke Therapeutics Inc (NASDAQ:STOK) is set to release its Q2 2025 earnings on Aug 12, 2025. The consensus estimate for Q2 ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

STOK Company Profile Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

The lawsuit claims that Chobani is free-riding on Danone’s brand equity and marketing investment in RTD coffee by copying ...

Wrexham ’s historic Racecourse Ground will become known as the SToK Racecourse under the terms of a new sponsorship deal brokered by Hollywood owners Ryan Reynolds and Rob McElhenney. This is ...

Wrexham have released images of revised plans for a new Kop stand at their Stok Racecourse home. Revised designs for the new 5,500-capacity Kop Stand have been presented to Wrexham County Borough ...

Wrexham striker Ollie Palmer has scored two goals in the space of a minute in stoppage time then converted one of the team’s ...